Fig. 6: Transcriptomic analysis of co-treatment with BETi and bevacizumab in ECs.
From: Three-dimensional CRISPR screening reveals epigenetic interaction with anti-angiogenic therapy
a Schematic representation of transcriptomic analysis using RNA-Seq. b, c Heat map (b) and volcano plots (c) showing normalized expression dynamics of DEGs identified based on their differential expression (FDR < 0.05 and |log2 fold-change| > 1) in the comparison between bevacizumab-treated versus palivizumab-treated ECs in ESFM plus I-BET762 or JQ1 but not DMSO. DEGs are highlighted in red in volcano plots. d Gene sets enriched in ECs treated with palivizumab and I-BET762 (FDR ≤ 0.3) or JQ1 (FDR ≤ 0.2), FDR indicated by red dashed lines. e Enrichment plots of the gene set enriched in both conditions of palivizumab plus I-BET762 and palivizumab plus JQ1 (indicated by red arrowheads in d). Results represent three independent experiments (n = 3).
